Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099005 | 0.82 | TP53 (0.35) | TP53MAPTTHRBMEN1KMT2A | |
| SCHEMBL4090468 | 0.81 | MAPT (0.39) | TP53MAPTSMN1; SMN2THRBCNR2 | |
| SCHEMBL4102167 | 0.80 | TP53 (0.37) | TP53MAPTTHRBCNR2DHFR | |
| SCHEMBL4100808 | 0.78 | NPC1 (0.34) | TP53 | |
| SCHEMBL4091444 | 0.78 | TRPA1 (0.40) | MDM2CNR2CRHR1 | |
| SCHEMBL4102486 | 0.74 | MAPT (0.34) | TP53MAPTCNR2CYP3A4 | |
| SCHEMBL4106573 | 0.69 | TRPA1 (0.34) | — | |
| SCHEMBL4106287 | 0.69 | SMN1; SMN2 (0.35) | MAPTCYP2C19SMN1; SMN2CRHR1DHFR | |
| SCHEMBL4105507 | 0.69 | GRIN1 (0.42) | MAPTCNR2DHFR | |
| SCHEMBL4097513 | 0.67 | PDE5A (0.35) | CYP2C19KMT2ACRHR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | TP53 3977/4885MAPT 3587/4885CYP2C9 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.